From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Utility decrements
Cycle rates (%)
Ustekinumab [23,24,25]
Adalimumab [40, 41, 48, 51, 52]
Vedolizumab [39, 53]
Serious infection
− 0.52 [54]
0.34
0.32
Tuberculosis
− 0.55 [55]
0.00
Lymphoma
− 0.20 [56]
Hypersensitivity
− 0.11 [57]
0.01
Skin reactions
− 0.03 [58]
0.75
10.37
0.59